- Home
- TALO vs SLNO Comparison
TALO vs SLNO Comparison
Compare TALO & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TALO | SLNO |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.5B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | TALO | SLNO |
|---|---|---|
| Price | $10.70 | $49.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $14.30 | ★ $110.90 |
| AVG Volume (30 Days) | ★ 2.1M | 1.6M |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,872,554,000.00 | $98,675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $155.86 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.06 | N/A |
| 52 Week Low | $6.23 | $41.50 |
| 52 Week High | $12.20 | $90.32 |
Technical Indicators
Market Signals| Indicator | TALO | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 43.40 | 46.11 |
| Support Level | $11.55 | $48.60 |
| Resistance Level | $11.96 | $52.85 |
| Average True Range (ATR) | 0.38 | 2.59 |
| MACD | -0.13 | 0.58 |
| Stochastic Oscillator | 2.27 | 26.48 |
Price Performance
Historical ComparisonAbout TALO Talos Energy Inc.
Talos Energy Inc is an independent oil and gas company predominantly involved in offshore exploration and production. The company has operations in the United States, the Gulf of Mexico, and offshore Mexico. The company's operating segments are; exploration and production of oil, natural gas and NGLs, and the CCS segment. The revenue is generated from the sale of oil, natural gas, and NGL quantities sold to purchasers.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.